OR WAIT null SECS
December 19, 2025
Article
Topline results show GLPG3667 met its primary endpoint in a phase 3-enabling dermatomyositis trial but missed in systemic lupus erythematosus.
December 15, 2025
A BTK inhibitor, orelabrutib, met its primary endpoint in a phase 2b trial for systemic lupus erythematosus, with further approval for a phase 3 trial evaluation.
November 24, 2025
Video
At ACR 2025, Dapas discusses how polygenic risk scores link genetic risk to SLICC criteria, advancing precision medicine in systemic lupus erythematosus.
November 18, 2025
Ramsey-Goldman emphasized the importance of QoL in lupus, looking beyond disease scores.
Ramsey-Goldman discussed the potential of NAC for treating systemic lupus erythematosus.
November 15, 2025
A compilation of 13 trials presented as late-breaking data at ACR Convergence 2025.
November 08, 2025
Podcast
Discover groundbreaking insights on lupus nephritis treatment from the REGENCY trial, highlighting the impact of obintuzumab on patient outcomes.
November 06, 2025
The rheumatology month in review emphasizes new data presented at the 2025 ACR Convergence.
Cuda also discussed further research she'd like to do with cognition and SLE.
Cuda discussed the potential of the NIH toolbox to easily assess cognitive effects in clinical trials.
